WallStSmart

CoStar Group Inc (CSGP)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CoStar Group Inc generates 49927% more annual revenue ($3.41B vs $6.82M). CSGP leads profitability with a 0.7% profit margin vs -40.7%. CSGP earns a higher WallStSmart Score of 54/100 (C-).

CSGP

Buy

54

out of 100

Grade: C-

Growth: 6.0Profit: 3.5Value: 7.3Quality: 8.0
Piotroski: 2/9Altman Z: 3.10

EUDA

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -47.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CSGPUndervalued (+89.2%)

Margin of Safety

+89.2%

Fair Value

$444.62

Current Price

$33.89

$410.73 discount

UndervaluedFair: $444.62Overvalued

Intrinsic value data unavailable for EUDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CSGP5 strengths · Avg: 9.0/10
PEG RatioValuation
0.1210/10

Growing faster than its price suggests

Altman Z-ScoreHealth
3.1010/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
22.5%8/10

Revenue surging 22.5% year-over-year

EUDA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.9%10/10

Revenue surging 78.9% year-over-year

Debt/EquityHealth
-0.5610/10

Conservative balance sheet, low leverage

Areas to Watch

CSGP4 concerns · Avg: 3.0/10
Return on EquityProfitability
0.3%3/10

ROE of 0.3% — below average capital efficiency

Profit MarginProfitability
0.7%3/10

0.7% margin — thin

Operating MarginProfitability
0.3%3/10

Operating margin of 0.3%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EUDA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$48.09M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-2.53M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CSGP

The strongest argument for CSGP centers on PEG Ratio, Altman Z-Score, Debt/Equity. Revenue growth of 22.5% demonstrates continued momentum. PEG of 0.12 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on Revenue Growth, Debt/Equity. Revenue growth of 78.9% demonstrates continued momentum.

Bear Case : CSGP

The primary concerns for CSGP are Return on Equity, Profit Margin, Operating Margin. A P/E of 469.1x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

CSGP profiles as a growth stock while EUDA is a hypergrowth play — different risk/reward profiles.

CSGP carries more volatility with a beta of 0.72 — expect wider price swings.

EUDA is growing revenue faster at 78.9% — sustainability is the question.

CSGP generates stronger free cash flow (98M), providing more financial flexibility.

Bottom Line

CSGP scores higher overall (54/100 vs 24/100) and 22.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CoStar Group Inc

REAL ESTATE · REAL ESTATE SERVICES · USA

CoStar Group, Inc. provides online market information, analysis and services to the commercial real estate, hospitality, residential and related professional industries in the United States, Canada, Europe, Asia Pacific and Latin America. The company is headquartered in Washington, the District of Columbia.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical innovator dedicated to the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. The company utilizes cutting-edge technologies and maintains a strong clinical pipeline, emphasizing supportive care and immune modulation. With a deep commitment to research and development, EUDA is strategically positioned to drive healthcare advancements, improve patient outcomes, and broaden access to vital medical treatments.

Visit Website →

Want to dig deeper into these stocks?